Insider Buying: PureTech Health (LON:PRTC) Insider Buys £939.44 in Stock

PureTech Health plc (LON:PRTC) insider Kiran Mazumdar Shaw bought 93,944 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was bought at an average cost of GBX 1 per share, with a total value of £939.44.

PureTech Health Price Performance

PRTC stock opened at GBX 119.12 on Monday. The company has a 50 day simple moving average of GBX 127.34 and a 200 day simple moving average of GBX 126.62. The stock has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. PureTech Health plc has a 1 year low of GBX 104.71 and a 1 year high of GBX 146.40. The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51.

Analysts Set New Price Targets

Separately, Peel Hunt reissued a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.